HIV-associated opportunistic infections - Going, going, but not gone: The continued need for prevention and treatment guidelines

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages 609-611

  Brooks, John T ^a,e   Kaplan, Jonathan E ^a   Holmes, King K ^b   Benson, Constance ^c   Pau, Alice ^d   Masur, Henry ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VARICELLA ZOSTER VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DELAYED DIAGNOSIS; HEALTH CARE SYSTEM; HERPES ZOSTER; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MORTALITY; MYCOBACTERIUM INTRACELLULARE AVIUM; OPPORTUNISTIC INFECTION; OUTPATIENT CARE; PNEUMOCYSTIS JIROVECI; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; VIRUS INFECTION; AIDS RELATED COMPLEX; REVIEW; UNITED STATES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 60549112454     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596756     Document Type: Short Survey

References (23)

1. Bonnet F, Lewden C, May T, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 2005; 37:482-7.
2. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40:609-16.
3. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
4. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-9.
5. Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008; 22:1345-54.
6. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents - recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2004; 53(RR-15):1-112. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5315.pdf. Accessed 13 January 2009.
7. Centers for Disease Control and Prevention. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989; 38(Suppl 5):1-9.
8. US Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. MMWR Recomm Rep 1993; 42(RR-9):14-20. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4209.pdf. Accessed 13 January 2009.
9. US Public Health Service, Infectious Diseases Society of America. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Recomm Rep 1995; 44(RR-8):1-34. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4408. pdf. Accessed 13 January 2009.
10. US Public Health Service/Infectious Diseases Society of America Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep 1997; 46(RR-12):1-46. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4612.pdf. Accessed 13 January 2009.
11. US Public Health Service, Infectious Diseases Society of America. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep 1999; 48(RR-10):1-59, 61-6. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4810.pdf. Accessed 13 January 2009.
12. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51(RR-8):1-52. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5108. pdf. Accessed 13 January 2009.
13. Sackoff JE, Shin SS. Trends in immunologic and clinical status of newly diagnosed HIV-positive patients initiating care in the HAART era. J Acquir Immune Defic Syndr 2001; 28:270-2.
14. Centers for Disease Control and Prevention. Late versus early testing of HIV - 16 sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep 2003; 52:581-6.
15. Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S. Late diagnosis of HIV infection - trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr 2006; 43:491-4.
16. Mugavero MJ, Castellano C, Edelman D, Hicks C. Late diagnosis of HIV infection: the role of age and sex. Am J Med 2007; 120:370-3.
17. Lyons MS, Lindsell CJ, Hawkins DA, Raab DL, Trott AT, Fichtenbaum CJ. Contributions to early HIV diagnosis among patients linked to care vary by test measure. BMC Public Health 2008; 8:220-30.
18. Gandhi NR, Skanderson M, Gordon KS, Concato J, Justice AC. Delayed presentation for human immunodeficiency (HIV) care among veterans. Med Care 2007; 45:1105-9.
19. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007; 45:1369-74.
20. Dorrucci M, Rezza G, Porter K, Phillips A; The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration. Temporal trends in postseroconversion CD4 cell count and HIV load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195:525-34.
21. Crum-Cianflone NF, Eberly L, Zhang Y, et al. Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters across the HIV epidemic: 1985-2007 [abstract H-4051]. In: Program and abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting. (Washington, DC). Washington, DC: American Society for Microbiology; and Alexandria, VA: Infectious Diseases Society of America, 2008.
22. Centers for Disease Control and Prevention. Persons tested for HIV - United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:845-9.
23. Branson BM, Hunter Handsfield H, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep 2006; 55(RR014):1-8, 9-16.